STAT+: Lilly wins approval for once-weekly insulin shot
The FDA approved Onswik, Lilly’s once-weekly basal insulin for adults with type 2 diabetes.
TL;DR
- Lilly said the FDA approved Onswik, its once-weekly basal insulin for adults with type 2 diabetes.
- The company said the approval was based on its QWINT Phase 3 program involving more than 3,400 adults.
- The announcement expands Lilly’s marketed diabetes portfolio; the clinical and safety details cited here come from the company release.
STAT reported the FDA approval of Lilly’s once-weekly insulin shot. Lilly’s release identifies the product as Onswik (insulin efsitora alfa-gobe), a basal insulin approved for adults with type 2 diabetes. [1] [2]
Lilly said the approval was supported by the QWINT Phase 3 program, which evaluated the treatment in more than 3,400 adults. Those trial and product details are company-reported in the announcement. [2]
Why it matters
The approval adds a once-weekly basal insulin to Lilly’s commercial diabetes portfolio, making the product a notable regulatory and competitive development in the insulin market.
Editor's note
Headline kept verbatim from the STAT feed. Regulatory and trial details are attributed to Lilly’s company release; no treatment guidance is included.